65%Confidence
0Views
SEC EDGARSource
2026-03-19Date
Summary
Catalyst Pharmaceuticals filed an amended 8-K, suggesting revisions to previous disclosures that may involve financial restatements or material event corrections. Pharmaceutical companies often amend filings to clarify drug development or commercialization updates.
Actionable: Immediately compare the amended filing against the original to identify material changes affecting drug pipeline valuation or financial projections.
AI Confidence: 65%
Data Points
companyCATALYST PHARMACEUTICALS, INC. (CPRX) (CIK 0001369568)
form8-K
date2026-03-19
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now